Lupin Limited — Investor Meet, 19-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** Lupin reported Q3 FY25 sales of INR 5,619 crores, marking a 10.6% YoY increase compared to INR 5,080 crores in Q3 FY24. Nine-month sales stood at INR 16,630 crores, up 12.7% YoY. The EBITDA margin expanded to 24.3%, the highest in five years, while gross margins improved to 69.4%. Key growth drivers include a robust US business with sales of USD 235 million (+10.5% YoY) and a notable performance in EMEA (+20.9% YoY).

2. **Future Outlook and Growth Drivers:** Management is optimistic about continued growth, particularly in the US segment, planning to evolve toward a more complex product portfolio. Upcoming product launches include Tolvaptan and injectables such as Glucagon and Liraglutide. Expectations are set for double-digit revenue growth in FY25.

3. **Order Book and Operational Updates:** The pipeline remains strong with ongoing filings, including the recent submission of Ranibizumab in the EU and planned US filings. Significant investments in R&D are indicated, with projections for R&D expenditure reaching INR 1,800 crores for FY25.

4. **Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Analysts sought clarification on upcoming product launches, with management indicating key products like Glucagon could augment revenue momentum, despite competitive pricing pressures on certain generics.

- **Market Position and Competitive Landscape:** Concerns were raised about competition in respiratory therapies, but management expressed confidence in market share sustained through strategic partnerships and product differentiation.

- **Operational Challenges or Risks:** Management noted recent performance fluctuations in respiratory segments and ongoing litigation risks concerning Mirabegron but remained positive about overcoming these challenges.

- **Capex and Capital Allocation:** Analysts inquired about capital allocations, with emphasis on prioritizing investments in India and specialty areas, while smaller acquisitions would generally be targeted around USD 200-250 million.

- **Strategic Priorities and Long-Term Vision:** Management reiterated a shift towards specialty drugs and complex generics, anticipating improved margins over the next few years as they transition away from commoditized products.

5. **Market or Regulatory Updates:** Notably, Lupin continues to monitor potential US tariff impacts on pharmaceuticals, expressing hopes for exemptions given the industry's significant role in generic drug supply.

6. **Strategic Focus Areas:** The focus remains on enhancing R&D capabilities, particularly for complex and specialty drugs, and driving efficiencies to sustain margin improvements. Sustained investments in plant compliance and product pipelines are key themes.

7. **Investor Insight:** The financial health and growth trajectory suggest a bullish sentiment towards Lupin’s prospects. The anticipated product launches and sustained operational efficiencies support a strong case for a 'buy' position, especially in light of increased profitability and strategic alignment with market trends.